New drug shows promise for Long-Term fragile x management
Disease control
Ongoing
This 4-year study tests the long-term safety of the drug BPN14770 (zatolmilast) in 314 people with Fragile X syndrome who completed earlier trials. Participants include adult males and adolescents. The main goal is to see if the drug is safe over time, with secondary measures loo…
Phase: PHASE3 • Sponsor: Tetra Discovery Partners • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC